We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-2.9%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.2B
AUM Growth
-$2.13B
Cap. Flow
+$212M
Cap. Flow %
1.6%
Top 10 Hldgs %
51.27%
Holding
122
New
17
Increased
44
Reduced
28
Closed
23

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$853M
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$778M
3
AABA
Altaba Inc
AABA
+$385M
4
PPLI
People Inc
PPLI
+$348M
5
BABA icon
Alibaba
BABA
+$288M

Top Sells

Rank Stock Value
1
RHT
Red Hat Inc
RHT
+$964M
2
APC
Anadarko Petroleum
APC
+$738M
3
ARRY
Array Biopharma Inc
ARRY
+$394M
4
BKNG icon
Booking.com
BKNG
+$128M
5
EFX icon
Equifax
EFX
+$117M

Sector Composition

Rank Sector Weight
1 Healthcare 45.06%
2 Technology 13.07%
3 Communication Services 12.09%
4 Industrials 6.1%
5 Consumer Discretionary 5.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPL
26
DELISTED
Buckeye Partners, L.P.
BPL
$160M 1.21%
3,900,000
+3,180,143
+442% +$131M
ASND icon
27
Ascendis Pharma A/S
ASND
$16.6B
$149M 1.13%
1,550,000
+10,000
+0.6% +$1.12M
PANW icon
28
Palo Alto Networks
PANW
$292B
$124M 0.94%
+3,660,000
New +$130M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$31.6B
$121M 0.91%
1,500,000
+400,000
+36% +$31.6M
IOVA icon
30
Iovance Biotherapeutics
IOVA
$3.76B
$110M 0.83%
6,025,000
+300,000
+5% +$6.63M
AZN icon
31
AstraZeneca
AZN
$257B
$106M 0.8%
1,187,893
-862,107
-42% -$74.8M
MYOK
32
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$106M 0.8%
2,030,397
+30,397
+2% +$1.62M
SE icon
33
Sea Limited
SE
$72B
$104M 0.79%
3,375,000
– –
TRU icon
34
TransUnion
TRU
$16.2B
$102M 0.77%
1,255,138
-417,205
-25% -$33.5M
XLRN
35
DELISTED
Acceleron Pharma
XLRN
$94.8M 0.72%
2,400,000
+25,000
+1% +$1.08M
EFX icon
36
Equifax
EFX
$22.6B
$89.3M 0.67%
635,056
-828,723
-57% -$117M
GWR
37
DELISTED
Genesee & Wyoming Inc.
GWR
$86.5M 0.65%
782,673
+7,673
+1% +$845K
ALDR
38
DELISTED
Alder Biopharmaceuticals
ALDR
$78.6M 0.59%
+4,165,000
New +$47.6M
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
$78.2M 0.59%
1,612,069
+487,069
+43% +$25.4M
BRMK
40
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$77.3M 0.58%
+75,000,000
New +$778M
ENTA icon
41
Enanta Pharmaceuticals
ENTA
$392M
$76.6M 0.58%
1,274,212
+314,212
+33% +$23.3M
ABBV icon
42
AbbVie
ABBV
$468B
$75.7M 0.57%
+1,000,000
New +$68.6M
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$70.1M 0.53%
1,750,000
-250,000
-13% -$11.5M
GRFS
44
Grifois
GRFS
$5.44B
$62.4M 0.47%
3,113,222
+33,139
+1% +$711K
BKNG icon
45
Booking.com
BKNG
$158B
$61.1M 0.46%
778,475
-1,657,750
-68% -$128M
CY
46
DELISTED
Cypress Semiconductor
CY
$57.5M 0.43%
+2,464,966
New +$56.4M
CVS icon
47
CVS Health
CVS
$119B
$56.8M 0.43%
900,000
+77,500
+9% +$4.59M
RDUS
48
DELISTED
Radius Health, Inc.
RDUS
$52.9M 0.4%
2,054,486
+11,337
+0.6% +$278K
SAGE
49
DELISTED
Sage Therapeutics
SAGE
$52.3M 0.4%
372,800
-127,200
-25% -$21.3M
ZYME icon
50
Zymeworks
ZYME
$2.05B
$42.9M 0.32%
1,731,500
-24,970
-1% -$626K
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2019 Portfolio in Review

As of Q3 2019, Thomas Steyer held 122 positions worth $13.2B, down 14% from $15.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer's Q3 2019 filing shows 17 new, 44 increased, 28 reduced and 23 closed positions. Its largest new stake was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M. The largest sale was Red Hat Inc, an estimated $964M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 38% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2019 buy was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M.
  • Thomas Steyer added most to Allergan plc in Q3 2019, an estimated $853M increase.
  • Thomas Steyer's biggest Q3 2019 reduction was Booking.com, cutting an estimated $128M.
  • Thomas Steyer fully exited Red Hat Inc in Q3 2019, selling an estimated $964M.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.2B portfolio in Q3 2019.
  • Thomas Steyer opened 17 new positions and closed 23 in Q3 2019.
  • Thomas Steyer's portfolio value fell 14% quarter-over-quarter to $13.2B.

Based on Farallon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.